Dr Ravaud speaks with ecancertv at ESMO 2016 about results from a one-year trial of sunitinib vs placebo for post-nephrectomy high-risk renal cancer patients.
This phase III trial found a longer disease-free survival in the sunitinib arm, and Dr Ravaud describes this extension with the manageable toxicity profile as recommending factors for sunitinib in adjuvant therapy.
